title: Cardiovascular health and the menopause: the gynecologist as the patients' interface.
abstract: The large decrease in estrogen following menopause appears to explain the dramatic increase in cardiovascular disease (CVD) in postmenopausal women. Gynecologists are well placed to play a primary role in the diagnosis, prevention and management of CVD in these patients; this role may include advice on lifestyle changes, and, if appropriate, prescribing preventative treatments such as hormone replacement therapy (HRT) and lipid-lowering drugs. The use of estrogen replacement therapy (ERT) to prevent CVD is supported by a number of observational studies. However, recently, large, randomized trials gave unexpected, conflicting data on the cardiovascular benefits of HRT, leading to confusion, and influencing both patient and clinical perceptions regarding the role of HRT postmenopause. These different outcomes may be due to differences in the HRT regimens, mean age and mean time from menopause at enrollment, duration of therapy, and patient selection bias in observational studies. A 'unified hypothesis' consistent with findings from all studies has now been developed: HRT initiated at the time of the menopause prevents CVD, whereas HRT initiated years after the menopause seems to increase CHD events. This knowledge is essential for gynecologists making clinical decisions regarding HRT use.
authors.affiliation: Department of Obstetrics and Gynecology, Keck School of Medicine, University of Southern California, USA.
authors.forename: R D
authors.initials: RD
authors.lastname: Arias
mesh_terms: D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000517:prevention & control / Q000628:therapy; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D004967:Estrogens / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006176:Gynecology; D006801:Humans; D010819:Physician's Role; D017698:Postmenopause / Q000187:drug effects*
chemical_list: D004967:Estrogens